NanoX Nanoscale X-ray tissue imaging: understanding the pathophysiology of hepatitis E infection
- Coordinator
- University College Dublin, National University of Ireland, Dublin, Ireland
- Runs
- 1 June 2025 to 31 May 2031
- Status
- Running
- EU funding
- €6.1m
- Total cost
- €6.1m
- Partners
- 4 organisations in 3 countries
- Type
- European Research Council grant
- Grant agreement
- 101167089
What the project is doing
In the project's own words, from its summary on CORDIS.
A driving force behind biomedical innovation lies in disease prevention, diagnosis and treatment. This requires a comprehensive understanding of how pathogens exploit living organisms across molecular, cellular, organismal, and population levels. Treatment of disease often relies upon interventions that restore the normal structure and function of cells. However, it is currently challenging to visualise and quantify detailed cellular changes within whole tissues in response to disease.
Soft X-ray microscopy is a novel, exciting imaging modality which enables detailed structural and chemical imaging of whole cells without fixation or dyes. This technique is currently used to image cultured cells, but has yet to be applied to the examination of cells within the intricate 3D architecture of tissue with its complex cell-cell interactions. Imaging of diseased tissue in this way is crucial to gain meaningful insight into disease mechanisms, while remaining complementary to other imaging modalities and biological assays.
Project NanoX aims to tackle this challenge, by merging the skillsets of a world-leading team with synergistic expertise in infectious disease, physics and structural biology to pioneer several innovations – (i) a targeted micro-biopsy tool for rapid tissue extraction for soft X-ray microscopy, (ii) high-throughput nano-resolution 3D imaging of tissues, (iii) novel integrative data mining approaches, and (iv) unprecedented insights into the pathogenesis of hepatitis E virus (HEV), an important emerging zoonotic viral infection with no specific therapies or vaccines, in healthy and immune-compromised individuals.
The scientific and technological innovations that will be developed and deployed by NanoX will revolutionize clinical diagnostics and research by providing new ways to directly image, characterise, diagnose, and treat diseases in any species at a level of detail and complexity that was previously unattainable.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| University College Dublin, National University of Ireland, Dublin | Dublin | Ireland | Coordinator |
| Karlsruher Institut Fuer Technologie | Karlsruhe | Germany | Participant |
| Ruprecht-Karls-Universitaet Heidelberg | Heidelberg | Germany | Participant |
| University of Warwick | Coventry | United Kingdom | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI